Watch For Duplications on Discharge Med Lists With Soliqua and Lantus

January 2017

Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.

Lixisenatide (Adlyxin) is the sixth GLP-1 agonist for diabetes. Think of it as similar to Byetta...but it's once-daily instead of BID.

Soliqua is the first insulin/GLP-1 agonist combo to hit the market. It contains insulin glargine U-100 (Lantus) plus lixisenatide.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Infectious Diseases Incorporate Updated Best Practices to Further Reduce Surgical Site Infections
Critical Care Consider Neuromuscular Blockers for Acute Respiratory Distress Syndrome
Med Safety Standardize Continuous IV Concentrations to National Recommendations
Opioids Help Patients Safely Continue Their Buprenorphine While in the Hospital
New Drugs Watch For Duplications on Discharge Med Lists With Soliqua and Lantus
New Drugs Keep Different Weight Loss Meds Straight During Transitions of Care
Vaccines Give the Tdap Vaccine During 3rd Trimester Instead of Postpartum
Inhalers Try to Keep Patients on the Same Type of Inhaler Device
Cardiology Limit Dose and Duration of NSAIDs in High-CV-Risk Patients
Pediatrics Continue to Save Systemic Quinolones as a Last Resort in Kids
Dehydration Consider Diluted Apple Juice an Option for Mild Dehydration in Kids